| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.6 | 0.4 |
| Net income | -16.3 | 8.2 |
| EPS (diluted, $ a share) | $-1.63 | $0.94 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +68.9% |
|---|
10-Q filed with the SEC, NASDAQ: MCRB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Seres Therapeutics, Inc.: key numbers
- Share price
- $1.41Close, Nov 16
- Market cap
- $14.4M
- Shares outstanding
- 10.2MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Seres Therapeutics, Inc.
All →Seres Therapeutics Financial Results
Seres Therapeutics reported Q3 2026 financial results and announced plans to advance SER-155 into a study for the prevention of immune checkpoint inhibitor-related enterocolitis (irEC). The company expects to submit the study design to the FDA in Q1 2027 following positive investigator-sponsored trial results showing an 80% clinical response rate.
- Term
- Q3 2026
“The irEC IST provided promising evidence that orally administered SER-155 improved epithelial barrier integrity and reduced gastrointestinal inflammation without systemic immunosuppression and was well-tolerated in patients with ICI-induced enterocolitis.”
Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres
“We believe SER-155 may enable ICI patients, of whom there are currently estimated to be approximately 300,000 in the U.S. alone, to remain on their therapy by reducing the occurrence of irEC, which often requires the halting of life-saving cancer treatment.”
Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres
Seres Therapeutics Leadership Change
Marella Thorell, Executive Vice President and Chief Financial Officer of Seres Therapeutics, Inc., resigned from her positions effective November 15, 2026. She is expected to provide advisory services to the company following her departure to support an orderly transition.